Flow cytometric analysis of Human CD19 expression on Human PBMCs. Human PBMCs (peripheral blood mononuclear cells) were stained with FITC Mouse Anti-Human CD3 Antibody and PE mouse IgG1 Isotype Control (left panel) or PE Mouse Anti-Human CD19 Antibody (right panel) at 5 μl/test. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
PE Mouse Anti-Human CD19 Antibody (4G7)
PE Mouse Anti-Human CD19 Antibody (4G7)
Price:
Regular price
$135 USD
Regular price
Sale price
$135 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD19 |
| Location | Cell membrane |
| Accession | P15391 |
| Clone Number | 4G7 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1 |
| Isotype Control | S0B5756 |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | Human PBMC |
| Purification | Protein G |
| Concentration | 0.2 mg/ml |
| Conjugation | PE |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.09% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5μl per million cells in 100μl volume | Hu |
Background
CD19, also known as B-lymphocyte antigen CD19 or B-Lymphocyte Surface Antigen B4, is a 95 kDa type I transmembrane glycoprotein that belongs to the immunoglobulin superfamily and is encoded by the CD19 gene. It is primarily expressed on all B lineage cells, from early pro-B cells to plasma cells, and plays a crucial role in B cell development, activation, and signaling. As a co-receptor, CD19 enhances signaling through the B cell receptor (BCR) complex, lowering the threshold for B cell activation and promoting B cell proliferation and differentiation. It forms a complex with CD21, CD81, and other proteins, which helps in the recognition of antigens tagged with complement and amplifies BCR signaling. CD19 is also a biomarker for B cell-related diseases and a target for immunotherapies, including monoclonal antibodies and CAR-T cell therapies, due to its consistent expression on B cells and B cell malignancies.
Picture
Picture
FC
